Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company ...

In a report released today, Allison Bratzel from Piper Sandler maintained a Buy rating on Argenx Se, with a price target of $750.00. The company’s shares closed last Friday at $591.99. Take advantage ...

Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.

Institutional investors including Armistice Capital, RTW Investments, and Wellington Management have increased their exposure ...

Included in the open-label crossover SOGALDI-PEF study were adults with symptomatic heart failure (New York Heart Association ...

Vera Therapeutics' Phase 3 data on atacicept sparks optimism for IgAN treatment, but competition and market challenges may ...